Belladonna and Roxicodone drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Belladonna (belladonna) and Roxicodone (oxycodone hydrochloride). Common drug interactions include chronic kidney disease among females and diarrhoea among males.
The phase IV clinical study analyzes what interactions people have when they take Belladonna and Roxicodone. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.
What is Belladonna?
Belladonna has active ingredients of belladonna. It is often used in irritable bowel syndrome. eHealthMe is studying from 1,043 Belladonna users. Check the latest studies of Belladonna.
What is Roxicodone?
Roxicodone has active ingredients of oxycodone hydrochloride. It is often used in pain. eHealthMe is studying from 20,099 Roxicodone users. Check the latest studies of Roxicodone.
21 people who take Belladonna and Roxicodone together, and have interactions are studied.

What are the common drug interactions of Belladonna and Roxicodone, by gender? *:
female:
- Chronic kidney disease
- Death
- Renal failure (kidney dysfunction)
- Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
male:
- Diarrhoea
- Arthralgia (joint pain)
- Blood pressure increased
- Lymphadenopathy (disease or enlargement of lymph nodes)
- Peripheral swelling
- Abdominal pain
- Asthma
- Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
- Dehydration (dryness resulting from the removal of water)
- Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
What are the common drug interactions of Belladonna and Roxicodone, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
n/a
60+:
- Blood magnesium decreased
- Chronic kidney disease
- Death
- Metastases to lymph nodes (cancer spreads to lymph node)
- Nausea (feeling of having an urge to vomit)
- Neoplasm progression (growth of tumour)
- Renal failure (kidney dysfunction)
- Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
What are the existing conditions these people have? *
- Carcinoid Tumor: 19 people, 90.48%
* Approximation only. Some reports may have incomplete information.
Do you take Belladonna and Roxicodone?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
- Belladonna (1,043 reports)
- Roxicodone (20,099 reports)
Browse all drug interactions of Belladonna and Roxicodone:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Belladonna:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Roxicodone:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Belladonna and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Roxicodone and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on belladonna and oxycodone hydrochloride (the active ingredients of Belladonna and Roxicodone, respectively), and Belladonna and Roxicodone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Percocet cause Skin Hyperpigmentation? - now
- Could Acetaminophen cause Dermatitis Atopic Aggravated? - 4 seconds ago
- Depo-Subq Provera 104 vs. Loseasonique, side effect and effectiveness comparison - 5 seconds ago
- Food Poisoning and drugs of ingredients of pertuzumab - 5 seconds ago
- Drug interactions of Carafate and Ciprodex - 13 seconds ago
- Chronic Kidney Disease and drugs of ingredients of rimegepant sulfate - 16 seconds ago
- Vioxx and Cva for Women aged 20-29 - 18 seconds ago
- Could Biaxin cause Kyphosis? - 18 seconds ago
- Vioxx and Cerebrovascular Accident for Women aged 20-29 - 18 seconds ago
- Vioxx and Stroke for Women aged 20-29 - 18 seconds ago